Indaptus Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 13, 2026, disclosing a significant increase in cash and a sharply reduced operating loss compared to the prior year period.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $26,604,443 as of September 30, 2026, up from $8,507,628 as of December 31, 2025, according to the filing.
  • Shares outstanding: Common shares issued and outstanding rose to 133,242,324 as of September 30, 2026, compared to 2,167,324 as of December 31, 2025.
  • Pending share proceeds: The balance sheet reflected $20,549,933 in "proceeds received pending share issuance" as a current liability as of September 30, 2026.
  • Quarterly operating loss: Total operating expenses for the three months ended September 30, 2026 were $1,135,867, compared to $2,648,487 for the same period in 2025.
  • Nine-month operating loss: Total operating expenses for the nine months ended September 30, 2026 were $5,104,319, compared to $11,677,809 for the nine months ended September 30, 2025.
  • Accumulated deficit: The accumulated deficit reached $86,672,808 as of September 30, 2026, versus $81,288,099 as of December 31, 2025.
  • Shares authorized: Common stock authorized shares increased to 1,000,000,000 as of September 30, 2026, from 200,000,000 as of December 31, 2025.

Indaptus Therapeutics Financial Position and Operations for Q3 2026

Indaptus Therapeutics, Inc. (NASDAQ:INDP) reported its financial results for the quarter and nine months ended September 30, 2026 in a Form 10-Q filed November 13, 2026. According to the filing, cash and cash equivalents totaled $26,604,443 at the end of the quarter, a substantial increase from $8,507,628 at December 31, 2025. The company also reported $4,000,000 in short-term investments as of September 30, 2026, bringing total assets to $31,211,985, compared to $9,310,168 at year-end 2025.

The filing disclosed a notable change in the company's capital structure. Common shares issued and outstanding grew from 2,167,324 at December 31, 2025 to 133,242,324 at September 30, 2026, while the authorized share count increased from 200,000,000 to 1,000,000,000. As of December 31, 2025, 1,000,000 preferred shares were issued and outstanding; the filing states no preferred shares were issued and outstanding as of September 30, 2026. A current liability of $20,549,933 described as "proceeds received pending share issuance" appeared on the September 30, 2026 balance sheet with no corresponding balance at year-end 2025.

On the income statement, the company reported research and development expenses of $271,204 for the three months ended September 30, 2026, compared to $1,517,723 in the same period of 2025. General and administrative expenses were $864,663 for the quarter versus $1,130,764 a year earlier. For the nine-month period, R&D expense was $1,125,465, down from $6,495,677, and G&A expense was $3,978,854, down from $5,182,132. The filing also recorded a warrant repricing charge of $410,154 in other expense for the nine months ended September 30, 2026, with no comparable charge in the prior year period. The accumulated deficit as of September 30, 2026 was $86,672,808. The company identified itself as a non-accelerated filer and smaller reporting company.

What Was Disclosed

Indaptus Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, disclosing balance sheet data, operating expenses, capital structure changes including a large increase in shares outstanding, and a $20,549,933 pending share issuance liability. The filing contains forward-looking statements subject to the company's cautionary language.